Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CIMZIA vs ENBREL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Certolizumab pegol is a recombinant, humanized antibody Fab' fragment conjugated to polyethylene glycol (PEG) that binds and neutralizes human tumor necrosis factor alpha (TNFα), preventing its interaction with cell surface TNF receptors (TNFR p55 and p75). It also modulates immune responses by inhibiting TNFα-induced pro-inflammatory cytokine production and adhesion molecule expression.
Tumor necrosis factor (TNF) inhibitor; etanercept is a dimeric fusion protein consisting of the extracellular ligand-binding portion of human TNF receptor p75 linked to the Fc portion of human Ig G1. It binds to soluble and membrane-bound TNF, thereby blocking TNF-mediated inflammatory responses.
Crohn's disease (FDA approved for adults with moderately to severely active disease),Rheumatoid arthritis (FDA approved for adults with moderately to severely active disease),Psoriatic arthritis (FDA approved for adults),Ankylosing spondylitis (FDA approved for adults),Plaque psoriasis (off-label use),Axial spondyloarthritis (off-label use)
Rheumatoid arthritis (moderate to severe active RA in adults, alone or with methotrexate),Polyarticular juvenile idiopathic arthritis (moderate to severe active JIA in patients aged 2 years and older),Psoriatic arthritis (active Ps A in adults),Ankylosing spondylitis (active AS in adults),Plaque psoriasis (moderate to severe chronic plaque psoriasis in adults who are candidates for systemic therapy or phototherapy)
400 mg subcutaneously at weeks 0, 2, and 4, then 200 mg every 2 weeks or 400 mg every 4 weeks.
50 mg subcutaneous injection once weekly
14 days (range 11-17 days) following subcutaneous administration; supports every 2-week or monthly dosing intervals.
Approximately 102 hours (range 68–170 hours) after subcutaneous administration in adults; prolonged in elderly and patients with renal impairment; supports every 2-week dosing.
Certolizumab pegol is a monoclonal antibody fragment that is not metabolized by cytochrome P450 enzymes. It is degraded by proteolysis into small peptides and amino acids.
Metabolism is via peptide hydrolysis and protein catabolism; no significant cytochrome P450 involvement.
Primarily eliminated via reticuloendothelial system and proteolytic catabolism; no significant renal or biliary excretion. Clinical pharmacokinetic studies show no dose adjustment needed in renal impairment.
Renal: negligible; Biliary/Fecal: not significantly eliminated; primarily degraded via proteolysis into amino acids.
Not applicable (monoclonal antibody); typically does not bind to serum proteins other than target antigen.
~96% bound, primarily to albumin and to a lesser extent to other plasma proteins.
~5.7 L (approx. 0.08 L/kg for a 70 kg patient), indicating predominant distribution in vascular space with limited extravascular penetration.
Approximately 0.18 L/kg (adults), indicating limited distribution primarily within the vascular and interstitial spaces; not extensively distributed into tissues.
Subcutaneous: ~80% (range 63-92%) relative to intravenous administration.
Subcutaneous: approximately 59% (range 50–76%) after a single 25 mg dose; absolute bioavailability not established for IV route; intramuscular route not recommended.
No dose adjustment required for renal impairment. Not studied in severe renal impairment.
No dose adjustment required for renal impairment. Not studied in patients with severe renal impairment.
No dose adjustment required for hepatic impairment. Not studied in severe hepatic impairment (Child-Pugh C).
No dose adjustment required for hepatic impairment. Not studied in patients with severe hepatic impairment.
Not approved for use in pediatric patients. Safety and efficacy not established.
For juvenile idiopathic arthritis (JIA) patients aged 2 years and older: 0.8 mg/kg (max 50 mg) subcutaneously once weekly.
No specific dose adjustment in elderly; use with caution due to increased infection risk.
No specific dose adjustment based on age alone; monitor for infections and adverse effects as elderly patients may have increased susceptibility.
Increased risk of serious infections leading to hospitalization or death, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to opportunistic pathogens. Malignancies, including lymphoma, have been reported in children and adolescents treated with TNF blockers.
Serious infections, including tuberculosis (TB), invasive fungal infections, and other opportunistic infections, have been reported. Patients should be screened for TB prior to therapy. Discontinue if serious infection develops. Malignancies, including lymphoma, have been reported in children and adolescents treated with TNF blockers.
Serious infections (reactivation of TB, fungal infections, bacterial sepsis), malignancies (including lymphoma and non-melanoma skin cancer), hepatitis B virus reactivation, demyelinating disease (e.g., multiple sclerosis), congestive heart failure (new onset or exacerbation), hematologic abnormalities (pancytopenia, aplastic anemia), hypersensitivity reactions (including anaphylaxis), and lupus-like syndrome.
Risk of serious infections (including TB, bacterial sepsis, invasive fungal infections),Hepatitis B reactivation,Malignancies (including lymphoma, leukemia, and other malignancies),Congestive heart failure (new onset or exacerbation),Demyelinating disorders (e.g., multiple sclerosis, optic neuritis),Hematologic abnormalities (including pancytopenia and aplastic anemia),Hypersensitivity reactions,Live vaccines should not be administered concurrently
Active serious infection, including sepsis, tuberculosis, and opportunistic infections. Known hypersensitivity to certolizumab pegol or any of its components.
Known hypersensitivity to etanercept or any component of the product,Sepsis or active infections (including chronic or localized infections)
No known food interactions. Take with or without food. No dietary restrictions required.
No specific food interactions have been reported with ENBREL. However, because ENBREL affects the immune system, patients should practice food safety to reduce infection risk (e.g., avoid undercooked meats, unpasteurized dairy).
CIMZIA (certolizumab pegol) is a PEGylated Fc-free anti-TNF monoclonal antibody. Due to minimal placental transfer (low Fc receptor binding), first trimester exposure shows no increased risk of major birth defects. Limited data in second and third trimesters; theoretical risk of immunosuppression in fetus. No known teratogenic effect in animal studies.
Etanercept is an Ig G1 fusion protein that undergoes active placental transfer, increasing from the first to third trimester. Limited human data show no clear increase in major birth defects or miscarriage, but there is a potential for immunosuppression in the neonate if used in the third trimester. Animal studies show no teratogenicity.
Minimal transfer into breast milk due to high molecular weight and PEGylation. M/P ratio not established. Consider benefits of breastfeeding vs risk of infant exposure. American Academy of Pediatrics considers compatible with breastfeeding.
Etanercept is excreted into breast milk in low amounts (M/P ratio approximately 0.001). Oral bioavailability is poor due to protein nature, so infant exposure is minimal. Compatible with breastfeeding, but monitor infant for infection or other adverse effects.
No standard dose adjustment required. Pharmacokinetics not significantly altered in pregnancy due to low placental transfer. Continue standard dosing; delay live vaccines in infants for 6 months after last maternal dose.
No standard dose adjustment recommended. However, due to increased clearance in later pregnancy, some clinicians may consider increasing dose or shortening interval to maintain efficacy, especially in the third trimester.
CIMZIA (certolizumab pegol) is a PEGylated Fc-free anti-TNF monoclonal antibody. It lacks an Fc region, which reduces placental transfer, making it a preferred biologic for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and Crohn's disease during pregnancy. Administer subcutaneously. Monitor for infections, including TB reactivation. Do not administer live vaccines concurrently. Injection site reactions are common; pre-medication with antihistamines may reduce them.
ENBREL (etanercept) is a TNF-alpha inhibitor used for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis, and polyarticular juvenile idiopathic arthritis. Monitor for infections, including tuberculosis reactivation. Do not administer live vaccines during therapy. Injection site reactions are common. If switching from other TNF inhibitors, consider washout period. ENBREL can be used in combination with methotrexate but avoid with other biologics.
Do not receive live vaccines (e.g., MMR, nasal flu, yellow fever) while on CIMZIA. Discuss vaccination schedule with your doctor.,Report any signs of infection (fever, cough, painful urination) or allergic reactions (rash, difficulty breathing) immediately.,Store CIMZIA in the refrigerator at 2°C to 8°C. Do not freeze. Protect from light. Allow to reach room temperature before injection.,Use proper injection technique; rotate injection sites (abdomen, thigh). Discard unused portions in a sharps container.,Tell your doctor if you are pregnant, plan to become pregnant, or are breastfeeding. CIMZIA has low placental transfer and may be used during pregnancy.
ENBREL is given as a subcutaneous injection, typically once or twice weekly. Proper injection technique and rotation of sites are important.,Do not take live vaccines (e.g., MMR, nasal flu, varicella) while on ENBREL.,Seek medical attention if you develop signs of infection (fever, chills, cough) or allergic reactions (rash, difficulty breathing).,Report any new or worsening neurological symptoms, such as numbness, tingling, or vision changes.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CIMZIA vs ENBREL, answered by our medical review team.
CIMZIA is a TNF-alpha Inhibitor that works by Certolizumab pegol is a recombinant, humanized antibody Fab' fragment conjugated to polyethylene glycol (PEG) that binds and neutralizes human tumor necrosis factor alpha (TNFα), preventing its interaction with cell surface TNF receptors (TNFR p55 and p75). It also modulates immune responses by inhibiting TNFα-induced pro-inflammatory cytokine production and adhesion molecule expression.. ENBREL is a TNF-alpha Inhibitor that works by Tumor necrosis factor (TNF) inhibitor; etanercept is a dimeric fusion protein consisting of the extracellular ligand-binding portion of human TNF receptor p75 linked to the Fc portion of human Ig G1. It binds to soluble and membrane-bound TNF, thereby blocking TNF-mediated inflammatory responses.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CIMZIA and ENBREL depend on the specific clinical indication. These are both TNF-alpha Inhibitor agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CIMZIA is: 400 mg subcutaneously at weeks 0, 2, and 4, then 200 mg every 2 weeks or 400 mg every 4 weeks.. The standard adult dose of ENBREL is: 50 mg subcutaneous injection once weekly. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CIMZIA and ENBREL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CIMZIA is classified as Category C. CIMZIA (certolizumab pegol) is a PEGylated Fc-free anti-TNF monoclonal antibody. Due to minimal placental transfer (low Fc receptor binding), first trimester exposure shows no incr. ENBREL is classified as Category C. Etanercept is an IgG1 fusion protein that undergoes active placental transfer, increasing from the first to third trimester. Limited human data show no clear increase in major birt. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.